BACKGROUND: The pain experienced by a patient during a prostate fusion biopsy is cumulative and can also be modulated by many factors. The aim of the study was to assess the association between the degree of pain intensity during prostate biopsy and the region of the biopted organ. MATERIALS AND METHODS: The study included a group of 143 patients who underwent prostate fusion biopsy under local analgesia followed by blockage of the periprostatic nerve. After a biopsy, the patients completed the original questionnaire about the pain experienced during the procedure. RESULTS: There was a statistically significant difference in pain score between cores taken in the apex (median 5 (IQR 2–5)), medium level (median 1 (IQR 1–2)), and prostate base (median 1 (IQR 1–3)) (p < 0.001). The malignancy scale ISUP ≥ 2 (p = 0.038) and lower PSA value (r = −0.17; p = 0.046) are associated with higher pain during procedure. Biopsy time was correlated with discomfort (r = 0.19; p = 0.04). Age (p = 0.65), lesion size (p = 0.29), PI-RADS score (p = 0.86), prostate volume (p = 0.22), and the number of cores (p = 0.56) did not correspond to the pain scale. CONCLUSIONS: The apex is the most sensitive sector of the prostate. ISUP ≥ 2 and patients with low PSA levels more often indicated higher values on the pain rating scale.

The increasing number of end-stage heart failure patients eligible for heart transplant and the disproportionately low number of donor hearts have led to increased interest in ventricular assist devices (VAD). These devices can be used as a bridge to decision, bridge to recovery, or bridge to...

The Central European Journal of Urology is an open access quarterly-issued journal, which provides a forum for the presentation of original clinical, experimental and other research studies...

Considering the fact that the majority of stents implanted during percutaneous coronary intervention are drug-eluting stents (DES) and 5–25% of patients require a non-cardiac surgery within 5 years of implanting the stent, appropriate therapeutic procedures in the perioperative period are clinically significant. To prevent late thrombosis in patients with implanted DES, it is recommended to prolong — compared to implantation of bare metal stents — dual antiplatelet therapy. In the perioperative period, it is crucial to maintain balance between the risk of a potentially fatal haemorrhage and stent thrombosis. Taking into account the fact that premature cessation of dual antiplatelet therapy is the most significant risk factor of stent thrombosis, correct perioperative actions in patients with high risk of bleeding may present many clinical difficulties. In the study, factors that impact the risk of thrombosis and haemorrhage, as well as up-to-date guidelines and methods regarding the perioperative period procedures in patients with implanted DES have been presented. Considering the fact that the majority of stents implanted during percutaneous coronary intervention are drug-eluting stents (DES) and 5–25% of patients require a non-cardiac surgery within 5 years of implanting the stent, appropriate therapeutic procedures in the perioperative period are clinically significant. To prevent late thrombosis in patients with implanted DES, it is recommended to prolong — compared to implantation of bare metal stents — dual antiplatelet therapy. In the perioperative period, it is crucial to maintain balance between the risk of a potentially fatal haemorrhage and stent thrombosis. Taking into account the fact that premature cessation of dual antiplatelet therapy is the most significant risk factor of stent thrombosis, correct perioperative actions in patients with high risk of bleeding may present many clinical difficulties. In the study, factors that impact the risk of thrombosis and haemorrhage, as well as up-to-date guidelines and methods regarding the perioperative period procedures in patients with implanted DES have been presented.